An account of dramatic relief can travel through a family faster than a careful explanation of treatment. Someone knows a person who received ketamine and felt different within days. A younger family member has read about neuroplasticity. A parent hears the possibility of an intervention after months of disappointment. Soon the conversation becomes whether the family can arrange it, before anyone has established exactly what “it” means.

Ketamine and esketamine belong in a serious conversation about depression. They also require more precision than the popular language surrounding them usually provides. The drug, its formulation, the clinical indication, the setting and the continuing plan are separate parts of the decision. Money can make a clinic accessible. It cannot make those parts interchangeable.

The most useful starting point is the person's actual clinical history: what has been assessed, which treatments have been tried, what happened, and what a treating clinician believes the next intervention is intended to change. A family can support that account without turning an appealing new treatment into a foregone conclusion.

Similar names, different clinical propositions

Esketamine is one molecular form of ketamine. Spravato is a specific esketamine nasal-spray product. In the United States, the FDA's prescribing information includes treatment-resistant depression in adults, either alone or with an oral antidepressant. It separately addresses depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, in conjunction with an oral antidepressant. These are defined indications, not approval for every form of distress.

Ketamine itself has an established anesthetic use. Clinicians also use it off-label in psychiatric practice. That phrase describes use outside an approved indication; it is neither a synonym for fraud nor a substitute for examining evidence and clinical judgment. The FDA stated in a June 2026 warning letter that ketamine is not FDA-approved for treating a psychiatric disorder. A compounded ketamine product should not be described as an approved equivalent of Spravato.

This distinction matters when a family compares offers. A nasal spray used in a restricted clinical program, an intravenous infusion in a clinic and a compounded product supplied for use elsewhere describe different arrangements. Their names may sit next to one another on a search-results page. Their evidence, supervision and practical requirements need individual examination. One service's approval or published study cannot simply be borrowed to validate another service.

The experience is not the outcome

People understandably remember the treatment session. They may describe a changed sense of time, emotional distance or unusual clarity. Those descriptions can be important to the person, but a striking experience does not by itself show that depression has improved in a durable, clinically meaningful way. An uncomfortable session does not, by itself, prove that treatment has failed either.

The useful question is what happens to the problem that brought the person into care. Can they begin ordinary activities again? Has persistent despair changed? Are they sleeping and eating differently? What does the treating team observe, and how does the person describe the difference? These are questions about a course of illness and recovery, not a demand that someone perform gratitude for a costly intervention.

For a family accustomed to obtaining visible results, an intense intervention can be especially persuasive. It has a beginning, a location and a bill. The less visible work afterward may appear secondary. Yet the person's life continues after the appointment: relationships, obligations, other treatment, opportunities for pleasure and the patterns that made everyday living difficult. A treatment decision should leave room for that whole picture.

NIMH's depression guidance describes assessment and treatment across psychotherapy, medicines and other interventions. A new option belongs within that wider clinical conversation. It should not require the family to dismiss everything that came before or to treat caution as a lack of ambition.

Monitoring is part of the treatment

Spravato's restricted program and observation requirements are part of the clinical proposition, rather than inconvenient bureaucracy around an otherwise simple purchase. Its labeling addresses sedation, dissociation, respiratory depression, misuse and blood-pressure changes, with observation after administration. The label also says that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated; improvement after a dose does not remove the possible need for hospitalization.

Those facts change the practical meaning of access. The relevant service includes screening, observation, a response to an adverse reaction and an agreed route for clinical questions afterward. A reassuring room and a reassuring manner are welcome, but they are not the same as the capacity to notice and manage a problem.

A family does not need to become a pharmacology team. It does need an intelligible explanation of the actual arrangement. Who has prescribing responsibility? Which existing clinician remains involved? What happens if the person feels worse between sessions? How will the service communicate with the person's chosen providers? A competent explanation should make the relationship understandable without making the patient carry every connection alone.

Hope without a family deadline

A young adult may feel pressure from two directions at once: their own wish to improve and a family's hope that a new intervention will restore the expected trajectory. The college return, the business role or the upcoming wedding can become an unspoken deadline. A disappointing response then feels like a failure to participate in the family's future.

That is too much responsibility to load onto a medical treatment. It also makes honest reporting harder. A person may minimize side effects, exaggerate improvement or avoid saying that the experience frightened them. Families can make more useful room by separating support from a required outcome. Funding care is a commitment to help someone receive appropriate treatment, not a contract for a particular personality or timetable.

The NICE shared-decision-making guideline, written for UK care, offers a useful principle: options make sense in relation to the person's priorities and circumstances. In a private-care conversation, that includes the option to ask more questions, seek another clinical opinion or decline a proposal. Financial generosity is strongest when it leaves those choices intact.

What would count as a good decision?

A good decision need not produce certainty about the result. It should produce clarity about why this intervention is being considered, what evidence applies, how risks are managed and how the person will be supported through the course of care. That standard is more demanding than a fashionable label and more realistic than a promise of transformation.

It also permits revision. A course of treatment may help, help partly, produce an unacceptable burden or fail to address the main problem. Each of those possibilities should lead back to the treating relationship, rather than to blame or an immediate search for the next expensive breakthrough.

For the family office, the enduring responsibility is continuity: protect time for treatment, make the actual arrangements workable and avoid turning medical experimentation into a status project. Paying for access can remove a barrier. The value of treatment still has to be understood through the person's experience and the clinician's assessment over time.